Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Sibutramine or its saltsPDL I DEC / 13
SigmodalC2 I JUN / 02
Sildenafil or its saltsPDL I DEC / 13
Silodosin or its salts or derivativesPDL I DEC / 13
SiltuximabPDL I DEC / 14
Silver nitrate II SEP / 98
Simeprevir or its saltsPDL I DEC / 13
SimvastatinPDL I DEC / 13
Sincalide II SEP / 98
Sirolimus or its derivativesPDL

including but not limited to everolimus, temsirolimus

I DEC / 13
Sitagliptin or its saltsPDL I DEC / 13
Sitaxentan or its saltsPDL I DEC / 13
Sodium acetate for parenteral use II SEP / 98
Sodium acetate in injectable form for parenteral nutrition I JAN / 03
Sodium biphosphate

for parenteral use

II SEP / 98
Sodium biphosphate.

cathartics

III SEP / 98
Sodium bromidePDL I DEC / 13
Sodium chloride single ingredient solutions for parenteral or ophthalmic use in concentrations of more than 0.9% [NOTE: Does not apply to contact lens solutions intended to be rinsed off prior to insertion into eye] II OCT / 98
Sodium chloride in injectable form for parenteral nutrition I JAN / 03
Sodium citrate for parenteral use II SEP / 98
Sodium cromoglicate (cromoglycate) in solutions in concentrations of 2% or less for ophthalmic or nasal use III SEP / 98
Sodium fluoride (see Fluoride)PDL

in solid oral dosage forms containing more than 1 mg of fluoride ion for human use

I DEC / 13
Sodium iodide for sclerosing II SEP / 98
Sodium iodine in injectable form for parenteral nutrition I JAN / 03
Sodium nitritePDL

when indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning

I JUN / 15
Sodium nitroprusside or its saltsPDL I DEC / 13
Sodium phosphate for parenteral use II SEP / 98
Sodium phosphate in injectable form for parenteral nutrition I JAN / 03
Sodium phosphate. cathartics III SEP / 98
Sodium picosulphate

for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)

II JAN / 10
Sodium polystyrene sulfonatePDL I DEC / 13
Sodium tartrate U
Sodium tetradecylsulfate II SEP / 98
Sofosbuvir or its saltsPDL I FEB / 14
Solifenacin or its saltsPDL I DEC / 13
SomatostatinPDL I DEC / 13
SomatremPDL I DEC / 13
SomatropinPDL I DEC / 13
Sorafenib and its saltsF1 I APR / 08
Sotalol and its saltsF1 I SEP / 98
Spectinomycin or its salts or derivativesPDL I DEC / 18
Spinosyn A and D isoformsPDL I DEC / 19
Spiramycin and its salts and derivativesF2 I SEP / 98
SpironolactonePDL I DEC / 13
StanozololC3 I JUN / 02
StavudinePDL I DEC / 13
StenboloneC3 I JUN / 02
StiripentolPDL I DEC / 13
Stramonium, its preparations, extracts and compounds II SEP / 98
Streptokinase as a debriding agent II SEP / 98
Streptokinase/streptodornase I SEP / 98
Streptomycin or its salts or derivativesPDL

For human use

I DEC / 18
Streptomycin or its salts or derivativesPDL

For veterinary use, including but not limited to dihydrostreptomycin

I DEC / 18
StreptozocinPDL I DEC / 13
Strontium and its salts for parenteral use II SEP / 98
Strontium bromidePDL I DEC / 13
Succinimide or its salts or derivativesPDL

except those compounds used for decontaminating water including but not limited to methsuximide 

I DEC / 13
Succinylcholine and its saltsF1 I SEP / 98
SucralfateF1 I SEP / 98
Sucroferric oxyhydroxidePDL I MAY / 18
SufentanilN I JUN / 02
Sugammadex or its saltsPDL I AUG / 16
Sulconazole or its saltsPDL I DEC / 13
Sulfinpyrazone or its saltsPDL I DEC / 13
Sulindac or its saltsPDL I DEC / 13
Sulphonamides or their salts or derivativesPDL

Including but not limited to Brinzolamide, succinylsulfathiazole, sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadoxine, sulfaguanidine, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfanilamide, sulfapyridine, sulfaquinoxaline, sulfasalazine, sulfathiazole, sulfisoxazole, sulphanilamide

I DEC / 18
Sulphones or their derivativesPDL

Including but not limited to dapsone 

I DEC / 13
Sumatriptan or its saltsPDL I DEC / 13
Sunitinib or its saltsPDL I DEC / 13
Suprofen or its saltsPDL I DEC / 13
Sutilains II SEP / 98
SuvorexantPDL I DEC / 18
Suxamethonium chloridePDL I DEC / 13
Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomersN

as listed in the schedules to the Controlled Drugs and Substances Act and the Narcotic Control Regulations

I JUL / 15
Tacrolimus or its derivativesPDL I DEC / 13
Tadalafil or its saltsPDL I DEC / 13
TalbutalC2 I JUN / 02
Taliglucerase alfaPDL I JUN / 14
Tamoxifen or its saltsPDL I DEC / 13
Tamsulosin or its saltsPDL I DEC / 13
TapentadolN (3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-phenol), its salts, derivatives and isomers and salts of derivatives and isomers I JAN / 16
TazarotenePDL I DEC / 13
Tazobactam or its salts or derivativesPDL I DEC / 13
Tedizolid or its salts or derivativesPDL

including but not limited to Tedizolid phosphate

I MAY / 15
TeduglutidePDL I OCT / 15
TeflubenzuronPDL I DEC / 13
Tegaserod or its saltsPDL I DEC / 13
Telaprevir or its derivativesPDL I DEC / 13
TelbivudinePDL I DEC / 13
Telmisartan or its salts or derivativesPDL I DEC / 13
Telotristat or its salts or derivativesPDL I NOV / 18
Temazepam and its saltsTS I SEP / 98
Temozolomide or its saltsPDL I DEC / 13
TeniposidePDL I DEC / 13
Tenofovir or its salts or derivativesPDL

Including but not limited to: tenofovir disoproxil, tenofovir alafenamide

I DEC / 13
Tenoxicam or its saltsPDL I DEC / 13
Tepoxalin or its derivativesPDL I DEC / 13
Terazosin or its saltsPDL I DEC / 13
Terbinafine or its saltsPDL I DEC / 13
Terbutaline or its saltsPDL I DEC / 13

2022 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drugs Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled